Scarica l'app Stockscreener
68.05
1.10%
0.74
Dopo l'orario di chiusura:
68.49
0.44
+0.65%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché HALO Giù?
Forum
Previsione
Precedente Chiudi:
$67.31
Aprire:
$67.33
Volume 24 ore:
1.16M
Relative Volume:
0.68
Capitalizzazione di mercato:
$8.06B
Reddito:
$1.40B
Utile/perdita netta:
$316.89M
Rapporto P/E:
27.31
EPS:
2.4918
Flusso di cassa netto:
$644.59M
1 W Prestazione:
+4.00%
1M Prestazione:
+6.90%
6M Prestazione:
+2.55%
1 anno Prestazione:
+11.05%
Intervallo 1D:
$67.11
$68.34
Intervallo di 1 settimana:
$65.22
$68.34
Portata 52W:
$47.50
$82.22
Halozyme Therapeutics Inc Stock (HALO) Company Profile
Nome
Halozyme Therapeutics Inc
Settore
Industria
Telefono
(858) 794-8889
Indirizzo
12390 EL CAMINO REAL, SAN DIEGO, CA
Compare HALO vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
HALO
Halozyme Therapeutics Inc
|
68.05 | 7.97B | 1.40B | 316.89M | 644.59M | 2.4918 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-04 | Downgrade | Goldman | Neutral → Sell |
| 2025-10-14 | Aggiornamento | Leerink Partners | Underperform → Market Perform |
| 2025-08-06 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-07-10 | Ripresa | Goldman | Neutral |
| 2025-05-14 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-13 | Downgrade | Leerink Partners | Market Perform → Underperform |
| 2024-10-07 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-09-19 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-06-07 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2024-02-29 | Iniziato | TD Cowen | Outperform |
| 2023-07-24 | Downgrade | Goldman | Buy → Neutral |
| 2023-07-24 | Iniziato | H.C. Wainwright | Buy |
| 2023-05-10 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | Ripresa | Berenberg | Buy |
| 2023-03-16 | Downgrade | SVB Securities | Outperform → Market Perform |
| 2022-12-21 | Ripresa | Morgan Stanley | Overweight |
| 2022-11-28 | Iniziato | Wells Fargo | Overweight |
| 2022-09-09 | Iniziato | Morgan Stanley | Overweight |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2021-06-14 | Iniziato | Evercore ISI | Outperform |
| 2021-05-17 | Iniziato | SVB Leerink | Outperform |
| 2021-05-11 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-01-21 | Reiterato | The Benchmark Company | Buy |
| 2020-12-17 | Iniziato | Berenberg | Buy |
| 2020-09-14 | Ripresa | JP Morgan | Overweight |
| 2020-07-01 | Iniziato | The Benchmark Company | Buy |
| 2020-02-05 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2020-01-09 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2020-01-08 | Iniziato | Goldman | Buy |
| 2019-11-05 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2018-10-19 | Ripresa | Piper Jaffray | Neutral |
| 2018-05-11 | Downgrade | Barclays | Equal Weight → Underweight |
| 2018-01-24 | Iniziato | Goldman | Neutral |
| 2017-10-16 | Reiterato | Piper Jaffray | Overweight |
| 2017-01-06 | Downgrade | Citigroup | Buy → Neutral |
| 2016-11-03 | Iniziato | Deutsche Bank | Buy |
| 2015-12-04 | Iniziato | Wells Fargo | Outperform |
| 2015-11-18 | Iniziato | Citigroup | Buy |
| 2015-09-22 | Iniziato | Barclays | Overweight |
| 2015-06-22 | Reiterato | JP Morgan | Overweight |
| 2015-03-03 | Reiterato | UBS | Buy |
| 2015-02-18 | Reiterato | MLV & Co | Buy |
| 2015-01-08 | Reiterato | MLV & Co | Buy |
Mostra tutto
Halozyme Therapeutics Inc Borsa (HALO) Ultime notizie
CapEx per share of Halozyme Therapeutics, Inc. – BX:RV7 - TradingView — Track All Markets
Working capital per share of Halozyme Therapeutics, Inc. – BX:RV7 - TradingView — Track All Markets
Halozyme Therapeutics (HALO) appoints interim CFO amid growth plans - MSN
TD Cowen reiterates Halozyme stock Buy rating on royalty growth By Investing.com - Investing.com Canada
Paragon Capital Boosts Stake in Halozyme Therapeutics - National Today
A Look At Halozyme Therapeutics (HALO) Valuation After New Vertex Collaboration And Licensing Deal - Sahm
Halozyme Therapeutics Inc (HAM:RV7) Dividend - GuruFocus
Halozyme Vertex Hypercon Deal Opens New Royalty And Growth Pathways - Sahm
HALO (Halozyme Therapeutics) Dividends Paid - GuruFocus
HALO (Halozyme Therapeutics) Unearned Premiums - GuruFocus
Did Halozyme’s Vertex Hypercon Licensing Deal Just Shift Halozyme Therapeutics’ (HALO) Investment Narrative? - Yahoo Finance
Liquidity Mapping Around (HALO) Price Events - Stock Traders Daily
Halozyme (HALO) loses 9% on weak earnings - MSN
Halozyme Therapeutics, Inc.Common Stock (NQ: HALO - FinancialContent
Buy Signal: How liquid is Halozyme Therapeutics Inc stock2026 Price Momentum & Daily Oversold Bounce Ideas - baoquankhu1.vn
Halozyme Therapeutics Inc at Leerink Global Healthcare Conference Transcript - GuruFocus
Halozyme Therapeutics Inc (HAM:RV7) Stock Earnings Transcripts - GuruFocus
TD Cowen Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Maintains Target Price $96 - Moomoo
Morgan Stanley Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Maintains Target Price $94 - Moomoo
HALO Insider Trading: CEO Torley Acquires 10K Shares April 2026 - Meyka
Halozyme Therapeutics, Inc. (HALO) Stock Price, News, Quote & History - ca.finance.yahoo.com
Halozyme inks license agreement with Vertex - The Pharma Letter
Halozyme and Vertex sign deal for Hypercon technology - Yahoo Finance
Returns Recap: Is Halozyme Therapeutics Inc forming a bullish divergence2026 Support & Resistance & Detailed Earnings Play Strategies - baoquankhu1.vn
HALO Stock Price, Quote & Chart | HALOZYME THERAPEUTICS INC (NASDAQ:HALO) - ChartMill
LTS:0J2O PE Ratio: 25.55 — 11% Above Median - GuruFocus
Halozyme Therapeutics CEO Helen Torley sells $634,981 in stock By Investing.com - Investing.com India
Halozyme CEO Sells $635,000 in Shares - National Today
Halozyme Therapeutics CEO Helen Torley sells $634,981 in stock - Investing.com
Vertex Pharmaceuticals Inc stock: New Halozyme deal signals pipeline push - AD HOC NEWS
Halozyme Therapeutics Insider Sold Shares Worth $634,982, According to a Recent SEC Filing - marketscreener.com
Halozyme (NASDAQ: HALO) CEO sells 10,000 shares after option exercise - Stock Titan
H.C. Wainwright Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Maintains Target Price $90 - moomoo.com
Leerink reiterates Halozyme stock rating after Vertex deal By Investing.com - Investing.com Canada
Halozyme Unit Enters License Deal With Vertex Pharmaceuticals for Hypercon Technology - Moomoo
Halozyme (HALO) Unveils Partnership with Vertex for Drug Deliver - GuruFocus
Vertex Pharma in pact with Halozyme for Hypercon drug delivery tech - Seeking Alpha
Halozyme, Vertex Pharmaceuticals Enter Exclusive Collab & License Agreement - Contract Pharma
Halozyme announces global collaboration and license agreement with Vertex Pharmaceuticals for Hypercon(TM) technology - marketscreener.com
Vertex taps Halozyme tech to shrink injections for at-home use - Stock Titan
Insider Buy: Will Halozyme Therapeutics Inc benefit from seasonality2026 Price Swings & Daily Momentum Trading Reports - baoquankhu1.vn
Halozyme Therapeutics Insider Sold Shares Worth $2,592,237, According to a Recent SEC Filing - marketscreener.com
How Investors May Respond To Halozyme Therapeutics (HALO) Mixed Q4 Results And ENHANZE-Focused Guidance Shift - Sahm
Halozyme Therapeutics, Inc. (HALO) stock price, news, quote and history - Yahoo Finance Singapore
How The Investment Story Is Shifting For Halozyme Therapeutics (HALO) After Recent Analyst Calls - Yahoo Finance
Element Squared LLC Invests $1.19 Million in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme Therapeutics (HALO) Valuation Check After Robust Q4 Revenue Beat And Updated Growth Guidance - Sahm
Hedge Fund and Insider Trading News: Warren Buffett, George Soros, Steve Cohen, Ken Griffin, Brevan Howard, Tudor Investment Corp, L.B. Foster (FSTR), Halozyme Therapeutics Inc (HALO), and More - Insider Monkey
Tema Etfs LLC Invests $1.7M in Halozyme Therapeutics - National Today
Tema Etfs LLC Makes New $1.70 Million Investment in Halozyme Therapeutics, Inc. $HALO - marketbeat.com
Halozyme Therapeutics CEO sells $2.59 million in stock By Investing.com - Investing.com Canada
Halozyme Therapeutics Inc Azioni (HALO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.69%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):